RSV Structure, Replication, and Host Interaction Explained

Respiratory syncytial virus, better known as RSV, is an enveloped, single-stranded RNA virus that ranks among the leading causes of serious lung infections in infants, young children, and older adults.¹ Its biology is more elaborate than that of most of its relatives, and the details of how it builds itself, copies its genome, slips past the immune system, and damages airways have driven decades of research. Understanding those details has also been the key to designing the vaccines and antibody therapies that have recently reached the clinic.

What RSV Looks Like Up Close

RSV belongs to the family Paramyxoviridae, a group of viruses that carry their genetic material as a single, unsegmented strand of negative-sense RNA. “Negative-sense” just means the genome cannot be read directly by the cell’s protein-making machinery; it first has to be copied into a mirror-image strand. RSV is considered the most complex member of the family because it encodes more genes and proteins than its relatives.² Its genome codes for eleven proteins, ten of which end up in the mature virus particle.

The virus itself is wrapped in a lipid envelope stolen from the host cell membrane during its exit. Studding that envelope are three surface proteins, but the two that matter most for infection are the G protein and the F protein. G handles attachment, sticking the virus to the cell surface. F handles fusion, merging the viral envelope with the cell membrane so the virus’s interior contents can spill inside. Beneath the envelope sits the matrix (M) protein, which acts as a structural scaffold linking the outer shell to the inner machinery. Inside that shell, the RNA genome is coated by nucleoprotein (N), forming a tightly wound complex that protects the fragile RNA and serves as the template for all copying.

Attachment and the CX3CR1 Connection

Before RSV can do anything, it has to grab hold of the right cell. The G protein handles initial attachment, and its main target on human airway cells is a receptor called CX3CR1. This receptor normally binds a signaling molecule called fractalkine, which helps coordinate immune cell trafficking. RSV’s G protein contains a short amino acid motif that mimics fractalkine, letting the virus latch onto CX3CR1 and essentially hijack a piece of the immune system’s communication network.³

This receptor interaction turns out to be especially important on real airway tissue rather than the standard lab cell lines researchers typically use. Studies using primary human airway epithelial cultures found that the CX3C motif on the G protein was critical for infection in those cultures but not in immortalized cell lines, suggesting that lab-adapted cells can give a misleading picture of how RSV actually enters the airway.⁴ The practical implication is significant: neutralizing antibodies measured in standard lab assays may not predict real-world protection accurately, and the G protein deserves consideration as a vaccine target alongside the more widely studied F protein.

Getting Inside the Cell

Attachment is only the first step. The virus still needs to cross the cell membrane. RSV accomplishes this through a process called macropinocytosis, a form of bulk fluid uptake that cells normally use to sample their environment. When RSV contacts a cell, it triggers the cell to ruffle its membrane and engulf large volumes of surrounding fluid, pulling the virus inside along with it. Researchers confirmed this by showing that blocking a key enzyme involved in macropinocytosis reduced both RSV uptake and infection by about 90%.⁵

Once the virus is inside an endosome (the bubble of membrane formed during uptake), the F protein takes center stage. F is a spring-loaded molecular machine. In its prefusion form, it sits on the virus surface in a metastable state, storing the energy needed for membrane fusion. When triggered, it snaps irreversibly into a postfusion shape, driving the viral and cell membranes together and releasing the viral RNA complex into the cytoplasm.⁶ This dramatic structural rearrangement is central to understanding both how the virus works and how modern vaccines and therapies are designed to stop it.

The Copying Machinery

With its genome released into the cell’s cytoplasm, RSV needs to make two kinds of RNA: messenger RNA (mRNA) to produce viral proteins, and full-length copies of the genome to package into new virus particles. Both tasks fall to a complex built around the large protein (L), which functions as the viral RNA polymerase. L works in coordination with the phosphoprotein (P), which acts as its essential cofactor, the nucleoprotein (N) that coats the template, and a transcription factor called M2-1.⁷

M2-1 plays a particularly interesting role. It helps the polymerase read through the gene junctions on the RSV genome without falling off, ensuring that the longer genes farther from the start of the genome still get transcribed efficiently. The interaction between M2-1 and P is essential for this process: mutating specific amino acids in P that mediate binding to M2-1 prevents M2-1-dependent gene expression while leaving basic transcription from short templates intact.⁸

The Switch From Making Proteins to Making Genomes

Early in infection, the virus prioritizes mRNA production to flood the cell with viral proteins. But at some point, it needs to pivot toward copying full-length genomes for packaging into new particles. RSV manages this transition through a second product of the M2 gene: the M2-2 protein. When researchers knocked out M2-2, the virus produced several times more mRNA than normal but several times less genomic RNA, demonstrating that M2-2 acts as a regulatory switch that tilts the balance from transcription toward genome replication.⁹

The mechanism behind this switch involves phosphorylation of the P protein. M2-2’s ability to suppress transcription is mediated through changes in P’s phosphorylation state, and this regulation requires the involvement of two P molecules.¹⁰ Overexpressing M2-2 beyond normal levels actually shuts down viral replication entirely, which makes this protein a potential drug target: if you could artificially push M2-2 activity high enough, you might stall the infection.¹¹

Cytoplasmic Factories That Hide Viral RNA

RSV does not scatter its replication machinery randomly through the cytoplasm. Instead, it concentrates everything into dense, membrane-free droplets called inclusion bodies. These structures form through liquid-liquid phase separation, the same physical process that creates oil droplets in water. The interactions among N, P, M2-1, and RNA drive the formation of these condensates, with specific forms of each protein playing distinct roles: oligomeric N and tetrameric P are the main drivers, while M2-1 enhances droplet formation by increasing the number of molecular contacts holding the condensate together.¹²

These inclusion bodies are not just organizational conveniences. They serve a defensive purpose. One of the cell’s key antiviral weapons is the OAS-RNase L pathway, which detects double-stranded RNA (a byproduct of viral replication) and degrades it. RSV neatly sidesteps this defense by sequestering its double-stranded RNA inside inclusion bodies, keeping it hidden from the sensors that would trigger the degradation pathway. When researchers disrupted inclusion body formation, the previously hidden RNA leaked into the cytoplasm and activated the antiviral response.¹³ This finding highlights how the physical organization of the infection is itself an immune evasion strategy, not just a logistical feature.

Shutting Down Interferon Defenses

Beyond physically hiding its RNA, RSV actively sabotages the cell’s alarm system. The first-line defense a cell mounts against viral infection involves interferons, signaling proteins that alert neighboring cells and activate antiviral genes. RSV encodes two nonstructural proteins, NS1 and NS2, whose primary job is dismantling this response. NS1 and NS2 cause a steep drop in levels of STAT2, a protein essential for transmitting interferon signals inside the cell. Without STAT2, the cell cannot respond properly even when interferons are present.¹⁴

NS1 and NS2 also work together to suppress IRF-3, a transcription factor that helps switch on interferon production in the first place. Once both proteins are expressed at significant levels, they cooperatively block IRF-3 activation and its movement into the nucleus.¹⁵ The net effect is a virus that attacks the interferon system at multiple points simultaneously, both preventing interferon production and blocking the cell’s ability to respond to whatever interferon does get made. This double suppression helps explain why RSV can establish robust infections even in people who have been infected before.

Assembly and Escape

New RSV particles form at the cell surface, and the process is surprisingly selective about which proteins it requires. Three components are sufficient to build filamentous particles that resemble real virions: the phosphoprotein P, the matrix protein M, and the tail end of the fusion protein F. When all three are present, viral proteins coalesce and bud from the cell as long filaments. Remove any one of the three and the process breaks down or produces abnormal structures. Interestingly, M and F alone can still form filaments, but these are longer, thinner, and morphologically abnormal, suggesting P acts as a cofactor that controls particle shape and quality.¹⁶

Syncytia and Airway Damage

RSV gets its name from the giant, fused multi-cell structures it creates in infected tissue, called syncytia. The F protein does not just fuse the virus to a cell; it can also fuse neighboring cells together. This creates massive, dysfunctional sheets of merged cells that contribute to the sloughing of airway epithelium and obstruction of small airways. The cellular protein RhoA facilitates this process, with the interaction between F and RhoA promoting syncytium formation.¹⁷

The body is not completely defenseless against this tissue-damaging process. A receptor called RAGE, expressed in the lower airways, can interfere with F protein function and block syncytium formation without stopping the virus from entering cells or replicating. RAGE essentially limits the spread of damage rather than preventing infection outright, acting as a brake on the most destructive consequence of RSV’s fusion machinery.¹⁸

Immune Memory and Why Age Matters

The adaptive immune response to RSV involves both antibodies and T cells, but the balance matters. In experimental human infection studies, researchers found that virus-specific CD8+ T cells that reside permanently in lung tissue (displaying markers associated with long-term tissue residency) accumulate to high levels during recovery. People who had more of these resident memory T cells before infection experienced milder symptoms and lower viral loads, suggesting they provide meaningful protection when antibody defenses are overwhelmed.¹⁹

Age reshapes this response in important ways. In animal models comparing adult and aged hosts, older animals mounted a weaker inflammatory response overall, with reduced expression of key genes associated with antiviral defense, including interferon-beta and other markers of a robust immune response. By four weeks after infection, immune cells from adult animals showed strong skewing toward a type of response associated with viral clearance, while cells from aged animals showed a different pattern associated with less effective control of viral infections.²⁰ This age-related shift in immune polarization helps explain why RSV is disproportionately dangerous at both extremes of life, though the mechanisms differ: infants lack mature immunity, while older adults mount the wrong kind of response.

How RSV Keeps Evolving to Reinfect

Unlike measles, which provides lifelong immunity after a single infection, RSV reinfects people throughout their lives. One reason is the virus’s genetic diversity. RSV splits into two major antigenic groups, A and B, which can circulate simultaneously during the same season or alternate in dominance from year to year. When the same group dominates in consecutive years, the circulating viruses are genetically distinct from the previous year’s strains, giving them an edge against existing immunity.²¹

The G protein gene accumulates mutations far faster than the rest of the genome. Genomic analyses found that G had over 28 mutations per 100 nucleotides on average, while other genes ranged from 5 to 11%. The G gene also shows signs of strong positive selection, meaning mutations that change its amino acid sequence are actively favored, likely because they help the virus escape antibody recognition.²² Both subtypes evolve at comparable rates overall, though RSV-B’s G gene mutates slightly faster than RSV-A’s.²³

The Nasal Microbiome Connection

An increasingly recognized factor in RSV severity is the community of bacteria living in the nose. Research tracking infants through RSV infection found that the composition of the nasal microbiome correlated with disease severity in a stepwise fashion: the more severe the infection, the greater the deviation from a healthy microbial community. Certain bacteria, particularly those closely related to Streptococcus pneumoniae, were heavily enriched in severe cases. Meanwhile, bacteria thought to be protective, including Corynebacterium and Dolosigranulum species, became progressively more depleted as severity increased.²⁴

Co-infections involving RSV and bacteria are common, especially when the illness has progressed to pneumonia. The pathogens most frequently found alongside RSV include Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis, along with other respiratory viruses like rhinoviruses and influenza.²⁵ Whether these co-infections are a cause of worsening disease or a consequence of RSV-damaged airways being more vulnerable to secondary invaders remains an active area of investigation, but the microbiome data suggest the relationship runs in both directions.

How RSV Biology Shapes Vaccines and Antibody Therapies

Nearly everything described above feeds directly into how RSV vaccines and treatments are designed. The F protein’s dramatic shape-shift from prefusion to postfusion form turned out to be the central insight for vaccine development. Antibodies targeting the prefusion form of F are far more potent at neutralizing the virus than those targeting the postfusion form, so a major engineering challenge has been locking F in its prefusion shape long enough for it to serve as a vaccine antigen.

Researchers have pursued several strategies for this. One approach involves mutating a flexible region of the F protein to block the early structural changes that cascade into the full conformational rearrangement, effectively jamming the spring-loaded mechanism in its cocked position.²⁶ Another approach borrows from nature’s toolbox, using engineered dityrosine crosslinks to covalently bolt the prefusion structure in place, dramatically improving its stability and shelf-life.²⁷

Monoclonal antibody therapies take a complementary approach. Rather than training the immune system to produce its own antibodies, these therapies deliver prefabricated antibodies that lock the F protein in its prefusion form and prevent viral entry. The two leading candidates target different spots on F: nirsevimab binds antigenic site Ø on the protein’s head, while clesrovimab targets site IV.²⁸ Researchers have also identified a third antigenic site, designated site VIII, that occupies ground between sites II and Ø. Antibodies targeting site VIII show unusual breadth, cross-reacting with F proteins from both RSV subgroups A and B, making this site especially interesting for next-generation therapies.²⁹

Bovine RSV and What It Reveals About Host Specificity

Humans are not the only species troubled by RSV. Cattle have their own closely related virus, bovine RSV (BRSV), which causes strikingly similar respiratory disease in calves.³⁰ The two viruses share substantial genetic overlap. Their fusion proteins, for instance, are roughly 83 to 84% identical at the amino acid level.³¹

Despite that similarity, each virus is largely restricted to its own host species, and the NS proteins appear to be a major reason why. The NS1 and NS2 proteins from human and bovine RSV both counteract interferon responses, and they even cooperate across species in laboratory experiments. But their effectiveness is host-specific. A chimeric bovine RSV carrying human NS genes replicated normally in human cells and in cells that lacked interferon signaling, but was severely weakened in bovine cells with intact interferon responses.³² This means the NS proteins are not just immune evasion tools but also act as host-range determinants, fine-tuned by evolution to disarm the specific interferon defenses of each virus’s natural host. It is an elegant demonstration of how a virus’s ability to suppress immunity and its restriction to a particular species can be two sides of the same coin.